Recce Pharmaceuticals Ltd. · ASX:RCE

Recce Pharmaceuticals — Investor Presentation (February 2023)

27 slides from Recce Pharmaceuticals's investor presentation, February 2023

  1. Slide 1: Corporate Presentation

    Slide 1: Corporate Presentation

    Corporate Presentation February 2023 ASX:RCE FSE:R9Q

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer DISCLAIMER This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this pre

  3. Slide 3: Board Structure

    Slide 3: Board Structure

    Board Structure Dr John Prendergast James Graham Michele Dilizia Justin Ward Executive Chairman Chief Executive Officer Chief Scientific Officer Executive Director & (Shares: 250,000) (Shares: 6,031,932 – 3.39%) (Shares: 3,543,485 – 2.0%) Principal Quality Chemist (Options: 2,175,000) (Options: 2,25

  4. Slide 4: A Versatile Technology Platform

    Slide 4: A Versatile Technology Platform

    A Versatile Technology Platform R529 • Biotech company developing Anti-infectives targeting both bacterial and viral indications • Strong IP and own manufacturing capability • Qualified Infectious Disease Product designation • 10 years market exclusivity plus fast track approval* • Versatile deliver

  5. Slide 5: Strong Pipeline

    Slide 5: Strong Pipeline

    Strong Pipeline Over Various Indications and Upcoming Inflection Points Asset and Indications Discovery Pre-Clinical Phase I Phase II Phase III Market Route of Administration Serious/life threatening bacterial R327 Intravenous* infections including sepsis Urinary tract infections including urosepsis

  6. Slide 6: Sepsis – it’s a big problem!

    Slide 6: Sepsis – it’s a big problem!

    Sepsis – it’s a big problem! 2 What is Sepsis? Economic Impact Social Impact Sepsis is a life-threatening Is the most expensive Kills more people in the US inflammatory response to condition to treat in the than prostate, breast cancer infection that has spread in last 8 years5. and HIV/AIDS combine

  7. Slide 7: Sepsis Patient Journey

    Slide 7: Sepsis Patient Journey

    Sepsis Patient Journey Patient Presents at the Hospital Early treatment with the correct antibiotic is key to improving patient outcome • 1/3 of patients present non-specific symptoms, leading to delayed treatment and high mortality rate. • Mortality from sepsis increases by as much as 8% for every

  8. Slide 8: The Need for a New Class of Antibiotics: Synthetic Anti-Infectives

    Slide 8: The Need for a New Class of Antibiotics: Synthetic Anti-Infectives

    The Need for a New Class of Antibiotics: Synthetic Anti-Infectives • NO pre-formed natural superbugs. • Entirely man-made and designed with purpose. • Universal Mechanism of Action - does not succumb to resistance. • Broad Spectrum capability and maintains its activity even with repeated use. • Empo

  9. Slide 9: Independent Study Undertaken on R327 MoA

    Slide 9: Independent Study Undertaken on R327 MoA

    Independent Study Undertaken on R327 MoA1 By Leading Experts in Bacterial MoA Analysis Stage 1 Stage 2 R327 permeabilizes cell membrane and enters the cell R327 interrupts bacterial cellular energetics via ATP Synthesis Stage 3 Stage 4 Cellular division & non-dividing cell functions are disrupted R3

  10. Slide 10: RECCE 327 Multi-Layered Mechanism of Action

    Slide 10: RECCE 327 Multi-Layered Mechanism of Action

    RECCE® 327 Multi-Layered Mechanism of Action1 R327 rapidly & irreversibly R327 affects the assembly of R327 results in the shuts down cellular energetics bacterial cell division complex, decreased formation of the (adenosine triphosphate (ATP) components that require cellular bacterial cell division

  11. Slide 11: RECCE Activity Against Escherichia coli

    Slide 11: RECCE Activity Against Escherichia coli

    RECCE® 327 Activity Against Escherichia coli • E. coli grows fast. Eukaryotic cells healthy Without R327 R327 (3,000 ppm) and not affected. • R327 at 3,000 ppm shown to be highly effective against E. coli without affecting growing, healthy eukaryotic cells. • R327 rapidly and irreversibly shuts down

  12. Slide 12: RECCE Activity Against Staphylococcus aureus

    Slide 12: RECCE Activity Against Staphylococcus aureus

    RECCE® 327 Activity Against Staphylococcus aureus • S. aureus bacterial growth slower than E. coli, not Without R327 R327 (2,300 ppm) affecting eukaryotic cells. • R327 at 2,300 ppm shown to be highly effective against S. aureus without affecting growing, healthy eukaryotic cells. • R327 rapidly and

  13. Slide 13: Pre-Clinical Study Outlook

    Slide 13: Pre-Clinical Study Outlook

    Pre-Clinical Study Outlook • Recce’s new Anti-Infective Research (AIR) Unit: Fit-for-purpose laboratory space – Located within Murdoch Children’s Research Institute Dr Philip Sutton’s Pre-Clinical Update – Recce will streamline ongoing pre-clinical programs and explore new research development oppor

  14. Slide 14: Phase I Human Clinical Trial Complete

    Slide 14: Phase I Human Clinical Trial Complete

    Phase I Human Clinical Trial Complete 120x dose amount* 6,000 mg ✓ • Study to assess IV infusion of RECCE® 327 in healthy male subjects as a single High Dose 80x dose amount* 4,000 mg ✓ 7-10 subjects in each ascending dose. cohort: 2 control, 8 R327 40x dose amount* 2,000 mg ✓ • Randomized, double-b

  15. Slide 15: Phase I Human Clinical Trial – High Dose 6,000 mg

    Slide 15: Phase I Human Clinical Trial – High Dose 6,000 mg

    Phase I Human Clinical Trial – ‘High Dose’ 120x dose amount* 80x Why 6,000mg (R327) over 1 hour infusion? dose amount* 6,000 mg ✓ 40x dose amount* 4,000 mg ✓ • Study objectives achieved – Phase II preparations are underway 2,000 mg ✓ • R327 dosing broadly in efficacy range based on animal models – P

  16. Slide 16: R327 faster acting than existing antibiotics

    Slide 16: R327 faster acting than existing antibiotics

    R327 faster acting than existing antibiotics – no prolonged exposure needed E.coli Xen14 Biofilm 180000 • R327 kills pathogenic bacteria at a 150000 50% faster rate. 50%PEG PEG 120000 B0076 Untreated • R327 designed to work faster than all Luminescence* CEPH Cephalexin existing antibiotics, reinforc

  17. Slide 17: Reason for Optimism in Treating UTI/Sepsis

    Slide 17: Reason for Optimism in Treating UTI/Sepsis

    Reason for Optimism in Treating UTI/Sepsis Dr Alan Dunton’s Clinical Update Concentration of R327 in Ratio Urine Compared to Urine/Plasma - Plasma 15x 13x 15x 17x In over 60 healthy 14x subjects 20x 13x – R327 primary route of elimination appears to be – Opportunities for therapeutic in array of UTI

  18. Slide 18: RECCE Kills Quickly in the Urine

    Slide 18: RECCE Kills Quickly in the Urine

    RECCE® 327 Kills Quickly in the Urine E. coli ATCC 25922 Viable Cells Treated with RECCE® 327 in Urine + 10%LB 10.00 • R327 in the presence of human urine was able to 9.00 have a fast (near minutes effect against E. coli and irreversible 8.00 • Bacteria could not be ‘washed out’ and regrown 7.00 • R

  19. Slide 19: Background on UTIs

    Slide 19: Background on UTIs

    Background on UTIs • Urinary tract infection (UTI) is one of the most common infectious diseases • The most common pathogen causing UTIs is Escherichia coli (E. coli) with 62% One in three uncomplicated UTIs in young healthy ‒ The resistance among the isolates of E. coli are: ampicillin (86%), women

  20. Slide 20: Topical RECCE – Phase I/II

    Slide 20: Topical RECCE – Phase I/II

    Topical RECCE® 327 – Phase I/II Patient examples from ongoing Burn Wound trial • Patients suffered major burn injury. • Multiple bacterial species in and surrounding wound. • Growth swabs with organisms including pathogens from the ESKAPE group of bacteria. • Post R327 treatment: healthy skin growth

  21. Slide 21: Phase I/II Diabetic Foot Ulcer (DFU) Clinical Trial

    Slide 21: Phase I/II Diabetic Foot Ulcer (DFU) Clinical Trial

    Phase I/II Diabetic Foot Ulcer (DFU) Clinical Trial Clinical Trial Overview Market Opportunity • Human Research Ethics approval received • The total medical cost for treating diabetic • Phase I/II to assess safety and efficacy of R327 foot diseases in the United States is on mild skin and soft tissu

  22. Slide 22: Patents

    Slide 22: Patents

    Patents Four families across all major markets Patent Patent Patent Expiry Expiry Expiry Filed Family 1 Family 2 Family 3 Australia ✓ 2028 ✓ 2037 Accepted 2037 USA ✓ 2029 ✓ 2037 ✓ 2037 Europe ✓ 2028 ✓ 2037 ✓ 2037 Germany ✓ 2028 ✓ 2037 ✓ 2037 Spain ✓ 2028 ✓ 2037 ✓ 2037 France ✓ 2029 ✓ 2037 ✓ 2037 UK

  23. Slide 23: In-house Manufacturing Capabilities

    Slide 23: In-house Manufacturing Capabilities

    In-house Manufacturing Capabilities Manufacturing facility in Sydney’s Macquarie Park • Raw materials plentiful and cheap – few $/Kg • No expensive waste – 99.9% product yield • Automated manufacture process taking approx. 1 hour • 500 doses per fully automated run • Quality and Quantity demonstrate

  24. Slide 24: Recce Pharmaceuticals Ltd – Capital Structure

    Slide 24: Recce Pharmaceuticals Ltd – Capital Structure

    Recce Pharmaceuticals Ltd – Capital Structure 7% Snapshot Tickers ASX:RCE, FSE:R9Q Market Cap (approx.) AUD $102 million 28% Priced at AUD $0.572/share Top 20 Cash and deposits* AUD $8.05 million** Shareholder Distribution 30 January 2023 Outstanding shares 178.18 million Average daily volume 57.6k

  25. Slide 25: Upcoming Clinical Milestones

    Slide 25: Upcoming Clinical Milestones

    Upcoming Clinical Milestones • In-vivo pre-clinical Michele Dilizia Scientific Strategy Update ‒ Pre-Sepsis UTI Models in Rats ✓ • Phase I clinical trials ‒ R327 I.V. Single Dose, Safety/Tolerability/PK study in healthy subjects ✓ • Phase II UTI clinical trial (Pre-Sepsis) ‒ Single (as now completed

  26. Slide 26: Summary

    Slide 26: Summary

    Summary Proprietary new class of anti-infectives against bacteria and viruses, protected by Composition of Matter Patent. Fast development plans initially targeting: Sepsis, UTI, Burn wounds, Diabetic Foot Ulcers, COVID-19 and a suite of pre-clinical indications. Strong pre-clinical data package dem

  27. Slide 27: Thank you

    Slide 27: Thank you

    Thank you James Graham Managing Director and Chief Executive Officer Recce Pharmaceuticals Ltd ASX:RCE; FSE:R9Q +61 2 9256 2572 james.graham@recce.com.au recce.com.au

Source: Internet Archive copy of recce.com.au

More decks from Recce Pharmaceuticals Ltd.

All 45 Recce Pharmaceuticals decks